EP3155098A4 - Réparation de mutations et induction de tolérance du facteur viii et adnc, compositions, procédés et systèmes associés - Google Patents

Réparation de mutations et induction de tolérance du facteur viii et adnc, compositions, procédés et systèmes associés Download PDF

Info

Publication number
EP3155098A4
EP3155098A4 EP15807028.4A EP15807028A EP3155098A4 EP 3155098 A4 EP3155098 A4 EP 3155098A4 EP 15807028 A EP15807028 A EP 15807028A EP 3155098 A4 EP3155098 A4 EP 3155098A4
Authority
EP
European Patent Office
Prior art keywords
compositions
systems
methods
factor viii
tolerance induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15807028.4A
Other languages
German (de)
English (en)
Other versions
EP3155098A1 (fr
Inventor
Tom E. HOWARD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP3155098A1 publication Critical patent/EP3155098A1/fr
Publication of EP3155098A4 publication Critical patent/EP3155098A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP15807028.4A 2014-06-11 2015-06-11 Réparation de mutations et induction de tolérance du facteur viii et adnc, compositions, procédés et systèmes associés Withdrawn EP3155098A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462011019P 2014-06-11 2014-06-11
PCT/US2015/035399 WO2015191899A1 (fr) 2014-06-11 2015-06-11 Réparation de mutations et induction de tolérance du facteur viii et adnc, compositions, procédés et systèmes associés

Publications (2)

Publication Number Publication Date
EP3155098A1 EP3155098A1 (fr) 2017-04-19
EP3155098A4 true EP3155098A4 (fr) 2018-01-03

Family

ID=54834340

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15807028.4A Withdrawn EP3155098A4 (fr) 2014-06-11 2015-06-11 Réparation de mutations et induction de tolérance du facteur viii et adnc, compositions, procédés et systèmes associés

Country Status (3)

Country Link
EP (1) EP3155098A4 (fr)
CA (1) CA2951882A1 (fr)
WO (1) WO2015191899A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100256062A1 (en) 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
WO2013066438A2 (fr) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Évaluation et amélioration de la spécificité de clivage des nucléases
EP2928303A4 (fr) 2012-12-07 2016-07-13 Haplomics Inc Réparation de la mutation du facteur viii et induction de la tolérance
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
CA2956224A1 (fr) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Proteines cas9 comprenant des inteines dependant de ligands
EP4269577A3 (fr) 2015-10-23 2024-01-17 President and Fellows of Harvard College Éditeurs de nucleobases et leurs utilisations
WO2017112895A1 (fr) * 2015-12-23 2017-06-29 Haplomics, Inc. Réparation du gène f8
IL264565B1 (en) 2016-08-03 2024-03-01 Harvard College Adenosine nuclear base editors and their uses
EP3497214B1 (fr) 2016-08-09 2023-06-28 President and Fellows of Harvard College Protéines de fusion cas9-recombinase programmables et utilisations associées
WO2018039438A1 (fr) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation d'acides aminés non naturels dans des protéines au moyen de l'édition de bases
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
WO2018165504A1 (fr) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression de la douleur par édition de gène
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
EP3601562A1 (fr) 2017-03-23 2020-02-05 President and Fellows of Harvard College Éditeurs de nucléobase comprenant des protéines de liaison à l'adn programmable par acides nucléiques
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
EP3658573A1 (fr) 2017-07-28 2020-06-03 President and Fellows of Harvard College Procédés et compositions pour l'évolution d'éditeurs de bases à l'aide d'une évolution continue assistée par phage (pace)
WO2019139645A2 (fr) 2017-08-30 2019-07-18 President And Fellows Of Harvard College Éditeurs de bases à haut rendement comprenant une gam
WO2019079347A1 (fr) 2017-10-16 2019-04-25 The Broad Institute, Inc. Utilisations d'éditeurs de bases adénosine
AU2020221340A1 (en) 2019-02-15 2021-09-16 Bayer Healthcare Llc Gene editing for hemophilia A with improved Factor VIII expression
WO2020191246A1 (fr) 2019-03-19 2020-09-24 The Broad Institute, Inc. Procédés et compositions pour l'édition de séquences nucléotidiques
GB2614813A (en) 2020-05-08 2023-07-19 Harvard College Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000017375A2 (fr) * 1998-09-23 2000-03-30 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Procede de traitement de l'hemophilie par therapie genique in vivo a l'aide de vecteurs retroviraux

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010143917A2 (fr) * 2009-06-11 2010-12-16 Toolgen Incorporation Réagencements génomiques ciblés faisant intervenir des nucléases spécifiques de site
US9175280B2 (en) * 2010-10-12 2015-11-03 Sangamo Biosciences, Inc. Methods and compositions for treating hemophilia B
EP2928303A4 (fr) * 2012-12-07 2016-07-13 Haplomics Inc Réparation de la mutation du facteur viii et induction de la tolérance

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000017375A2 (fr) * 1998-09-23 2000-03-30 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Procede de traitement de l'hemophilie par therapie genique in vivo a l'aide de vecteurs retroviraux

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C.-Y. PARK ET AL: "Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 111, no. 25, 9 June 2014 (2014-06-09), US, pages 9253 - 9258, XP055277137, ISSN: 0027-8424, DOI: 10.1073/pnas.1323941111 *
LIN YI ET AL: "Use of blood outgrowth endothelial cells for gene therapy for hemophilia A", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 99, no. 2, 15 January 2002 (2002-01-15), pages 457 - 462, XP002430423, ISSN: 0006-4971, DOI: 10.1182/BLOOD.V99.2.457 *
MATSUI HIDETO ET AL: "Ex vivo gene therapy for hemophilia a that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors", STEM CELLS (MIAMISBURG), vol. 25, no. 10, 2007, pages 2660 - 2669, XP055426660, ISSN: 1066-5099 *
See also references of WO2015191899A1 *
WALSH C E: "GENE THERAPY PROGRESS AND PROSPECTS: GENE THERAPY FOR THE HEMOPHILIAS", GENE THERAPY, NATURE PUBLISHING GROUP, GB, vol. 10, no. 12, 1 June 2003 (2003-06-01), pages 999 - 1003, XP001155785, ISSN: 0969-7128, DOI: 10.1038/SJ.GT.3302024 *

Also Published As

Publication number Publication date
CA2951882A1 (fr) 2015-12-17
WO2015191899A9 (fr) 2017-05-11
WO2015191899A1 (fr) 2015-12-17
EP3155098A1 (fr) 2017-04-19

Similar Documents

Publication Publication Date Title
EP3155098A4 (fr) Réparation de mutations et induction de tolérance du facteur viii et adnc, compositions, procédés et systèmes associés
EP3280720A4 (fr) Compositions et procédés s'appliquant au conditionnement non myéloablatif
EP3209468A4 (fr) Robot de service client et systèmes et procédés associés
EP3189449A4 (fr) Système et procédé d'évaluation de sentiments
EP3377615A4 (fr) Compositions d'induction d'haploïdes et procédés d'utilisation associés
EP3107479A4 (fr) Articulations mécaniques, systèmes et procédés associés
EP3092286A4 (fr) Systèmes et procédés de conversion d'éthylène en liquides
EP3216313A4 (fr) Surface de cuisson
EP3115386A4 (fr) Composition d'isocyanurate
EP3380622A4 (fr) Méthodes et compositions pour modifier l'immunité
EP3175576A4 (fr) Génération et changement automatisés de mot de passe
EP3166613A4 (fr) Compositions et méthodes pour la réparation de la myéline
EP3135046A4 (fr) Systèmes et procédés pour générer des fonctionnalités basées sur la localisation
EP3194504A4 (fr) Polymères associatifs, et compositions, procédés et systèmes associés
EP3129719A4 (fr) Systèmes hvac et commandes
EP3134120A4 (fr) Compositions et méthodes pour le traitement de troubles liés aux cytokines
EP3189036A4 (fr) Compositions et méthodes pour traiter des troubles prolifératifs
EP3113798A4 (fr) Procédés et compositions pour modifier une réponse immunitaire
EP3120278A4 (fr) Procédés et systèmes de comparaison de génome
EP3114164A4 (fr) Compositions de revêtement durcissant à basses températures
EP3237937A4 (fr) Modélisation mésoscopique
EP3114315A4 (fr) Systèmes de géoguidage et procédés associés
EP3185746A4 (fr) Méthodes et systèmes de renforcement de la vision
EP3216315A4 (fr) Table de cuisson
EP3207093A4 (fr) Compositions de résines et leurs procédés de fabrication et d'utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170110

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20171130

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/12 20060101ALI20171124BHEP

Ipc: C07K 14/755 20060101ALI20171124BHEP

Ipc: C12N 15/09 20060101AFI20171124BHEP

Ipc: C12N 9/10 20060101ALI20171124BHEP

Ipc: C12N 9/16 20060101ALI20171124BHEP

Ipc: A61P 7/00 20060101ALI20171124BHEP

Ipc: A61K 48/00 20060101ALI20171124BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180703